MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
10.75
-0.52
-4.61%
Closed 16:00 12/05 EST
OPEN
11.16
PREV CLOSE
11.27
HIGH
11.24
LOW
10.70
VOLUME
164.34K
TURNOVER
--
52 WEEK HIGH
15.12
52 WEEK LOW
4.410
MARKET CAP
273.95M
P/E (TTM)
-8.2820
1D
5D
1M
3M
1Y
5Y
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Benzinga · 11/23 10:25
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
Benzinga · 11/23 07:48
Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 11/22 18:16
BRIEF-Actinium Announces Data From Phase 1 Actimab-A Clag-M Combination Trial
Reuters · 11/03 14:41
Actinium Announces 1-Year And 2-Year Overall Survival Data For Patients With Relapsed Or Refractory AML In Phase 1 Actimab-A CLAG-M Combination Trial
Benzinga · 11/03 13:21
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today highlighted positive results from the Phase 1 trial evaluating Actimab-A with salvage chemotherapy regimen CLAG-M i...
PR Newswire · 11/03 13:20
Actinium hits over two-year high as Novartis executive joins to lead Iomab-B sales
Seekingalpha · 11/02 17:37
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Benzinga · 11/01 07:31
More
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage, biopharmaceutical company. The Company is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Its clinical programs use its Antibody Warhead Enabling (AWE) technology platform. Its clinical pipeline is led by Antibody Radiation-Conjugates (ARCs). Its lead product candidate, Iomab-B (I-131 apamistamab), is a targeted conditioning agent, which consists of an anti-CD45 monoclonal antibody and the radioisotope Iodine-131 (I-131). Its clinical and preclinical development programs utilize multiple isotopes, including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies, including bone marrow transplant (BMT) and cancer therapeutics in combination with other therapeutic modalities.

Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.